Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Amitabh Chak MD

Amitabh Chak MD

Professor of Medicine and Oncology, Case Western Reserve University School of Medicine; Brenda and Marshall B. Brown Master Clinician in Innovation and Discovery, University Hospitals Cleveland Medical Center, Cleveland, Ohio

Dr. Chak is Professor of Medicine and Oncology at Case Western Reserve University School of Medicine and Brenda and Marshall B Brown Master Clinician in Innovation and Discovery at University Hospitals Cleveland Medical Center (UHCMC). His research interests include genetics of Barrett’s esophagus and its translational applications, endoscopic management of pancreaticobiliary disease, and EUS. At UHCMC he is former Director of Endoscopy and is currently the Director of Clinical Research in the Division and the Program Director of the Michael V. Sivak, Jr, Advanced Endoscopy Fellowship. At UHCMC he has received the Department of Medicine Educator Award, Best Research Mentor Award, Master Clinician Educator Award, and the Distinguished Clinical Physician Award. He served as Senior and Associate Editor for GIE for nine years and has also served ASGE on numerous committees as member, chaired the CME and the GIE Editorial Board committees, served on the ASGE Governing Board, and is a current member of the ASGE Foundation.


Dr Chak has founders shares and stock options in Lucid Diagnostics, serves as a consultant to Lucid Diagnostics, has sponsored research with Lucid Diagnostics, and has a royalty interest in patents licensed to Lucid Diagnostics. He also was a consultant in the past for Interpace Diagnostics, CDX, Cernostics, and receives research support from C2 Therapeutics/Pentax Inc. He is supported by National Institutes of Health grants U54CA163060 and P50CA150964.